References
- McClellan. Implementing value-based insurance products: a collaborative approach to health care transformation. The Brooking Institute; 2015. http://www.brookings.edu/wp-content/uploads/2016/06/Final-Brief-VBIP.pdf
- Garrison. Performance-based risk sharing arrangement: ISPOR good practice. 2013. [Cited Feb 2017]. Available from: http://www.ispor.org/TaskForces/documents/Performance-based-Risk-Sharing-Guidelines.pdf
- Jonsson B. Technology assessment for new oncology drugs. Clin Cancer Res. 2013;19(1):6–11.
- Kantarjian HM, Fojo T, Mathisen M, et al. Cancer drugs in the United States: justum pretium–the just price. J Clin Oncol. 2013;31(28):3600–3604.
- Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009;101(15):1044–1048.
- Godman B. Links between pharmaceutical R&D models and access to affordable medicines. A study for the ENVI COMMITTEE. 2016. [Cited Jan 2017]. Available from: www.europarl.europa.eu/RegData/etudes/STUD/2016/587321/IPOL_STU(2016)587321_EN.pdf
- Haycox A. Why cancer? Pharmacoeconomics. 2016;34(7):625–627.
- Simoens S, Picavet E, Dooms M, et al. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy. 2013;11(1):1–3.
- Cohen JP, Felix A. Are payers treating orphan drugs differently?. J Mark Access Health Policy. 2014;2:23513.
- Wild C, Grossmann N, Bonanno PV, et al. Utilisation of the ESMO-MCBS in practice of HTA. Ann Oncol. 2016;27(11):2134–2136.
- Godman B, Malmstrom RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8(1):77–94.
- Prescrire Editorial. New drugs, new indications in 2015: little progress, and threats to access to quality healthcare for all. Rev Prescrire. 2016;36:132–137.
- National Institute for H, Care E. Exploring the assesment and appraisal of regenerative medicines and cell therapy products. 2016. [Cited Feb 2017]. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/Science%20policy%20and%20research/regenerative-medicine-study-march2016-2.pdf
- Mestre F Multi-indication pricing; Pros, cons and applicability to the UK. P rFont34Bin0BinSub0Frac0Def1Margin0Margin0Jc1Indent1440Lim0Lim1. 2015. [Cited May 2017]. Available from: https://www.ohe.org/news/multi-indication-pricing-pros-cons-andapplicability-uk
- Grossmann N. Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval? ESMO Open. 2017;1:esmoopen-2016-000125.
- Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 2015;124:39–47.
- Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010;10:153.
- Ferrario A. Managed entry agreements for pharmaceuticals: the European experience. 2013. [Cited Dec 2016]. Available from: http://eprints.lse.ac.uk/50513/2013
- Godman B, Paterson K, Malmstrom RE, et al. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res. 2012;12(4):439–441.
- BioCentury. Back to school issue: paying the piper. 2014. [Cited May 2017]. Available from: http://www.biocentury.com/biotech-pharma-news/strategy/2014-09-01/22nd-biocentury-back-to-school-issue-time-to-try-new-pricing-schemes-a1
- Yadav. Differential pricing of pharmaceuticals. Review of current knowledge, new findings and ideas for action. A study conducted for the UK Department for International Developments. Spain; August 2010.
- Towse. European Union pharmaceutical markets: a case for differential pricing. International Journal of the Economics of Business. 2015 May 4;22(2):263–275.
- Garrison LP Jr. Rewarding value creation to promote innovation in oncology: the importance of considering the global product life cycle. Oncologist. 2010;15(Suppl 1):49–57.
- National Institute for H, Care E. Patient access schemes liaisons unit. 2016. [Cited Feb 2017]. Available from: https://www.nice.org.uk/about/what-we-do/patient-access-schemes-liaison-unit
- Scottish Medicines C. Patient access scheme guidence. 2016. [Cited May 2017]. Available from: https://www.scottishmedicines.org.uk/Submission_Process/Submission_guidance_and_forms/Patient-Access-Schemes
- Dranitsaris G, Dorward K, Owens RC, et al. What is a new drug worth? An innovative model for performance-based pricing. EurJ Cancer Care (Engl). 2015;24(3):313–320.
- Towse A, Garrison LP Jr. Can’t get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics. 2010;28(2):93–102.
- Ermisch M, Bucsics A, Vella Bonanno P, et al. Payers’ views of the changes arising through the possible adoption of adaptive pathways. Front Pharmacol. 2016;7:305.
- Espin. Experiences and impact of European risk-sharing schemes focusing on oncology medicines. 2011. Available form: http://whocc.geog.at
- Navarria A, Drago V, Gozzo L, et al. Do the current performance-based schemes in Italy really work? “Success fee”: a novel measure for cost-containment of drug expenditure. ValueHealth. 2015;18(1):131–136.
- Carlson JJ, Gries KS, Yeung K, et al. Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. ApplHealth EconHealth Policy. 2014;12(3):231–238.
- Garrison LP Jr., Carlson JJ, Bajaj PS, et al. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. AmJ ManagCare. 2015;21(9):632–640.
- Danzon P, Towse A, Mestre-Ferrandiz J. Value-based differential pricing: efficient prices for drugs in a global context. Health Econ. 2015;24(3):294–301.
- Van H Actual costs of cancer drugs in 15 European countries. 2016. [Cited Feb 2017]. Available from: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00486-6/fulltext
- Morgan SG, Vogler S, Wagner AK. Payers’ experiences with confidential pharmaceutical price discounts: a survey of public and statutory health systems in North America, Europe, and Australasia. Health Policy. 2017;121(4):354–362.
- Pepall. Industrial organization contemporary theory and empirical applications. 5th ed. Wiley. Online.
- Ascarza. When talk is “free”: the effect of tariff structure on usage under two- and three-part tariffs. Journal of Marketing Research. 2012 Dec;49(6):882–899.
- Lyengar. The impact of tariff structure on customer retention, usage, and profitability of access services. 2011. [Cited Feb 2017]. Available from: https://www0.gsb.columbia.edu/mygsb/faculty/research/pubfiles/4941/tariff_structure.pdf
- Harnisch. Exploring tariff-choice preference in B2B enterprise software acquistition settings. Tel Aviv, Twenty Second European Conference on Information Systems; 2014.
- National Bureau of Economics Research. Health insurance as a two-part pricing contract. [Cited Dec 2016]. Available from: http://www.nber.org/papers/w126812006
- Nash JF. Equilibrium points in N-person games. Proc Natl Acad Sci USA. 1950;36(1):48–49.
- Accelerated A. Accelerated access review; interim report. 2015. [Cited Feb 2017]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/471562/AAR_Interim_Report_acc.pdf
- Lambrecht. Paying too much and being happy about it: existence, causes and consequences of tariff-choice biases. J Marketing Res. 2006;43:212–223. Available from: http://www.jstor.org/stable/30163388?seq=1#page_scan_tab_contents
- Workman P, Draetta GF, Schellens JH, et al. How much longer will we put up with $100,000 cancer drugs? Cell. 2017;168(4):579–583.